NCT04729543View on ClinicalTrials.gov

MAGE-C2 TCR T Cell Trial to Treat Melanoma and Head and Neck Cancer

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

October 20, 2020

Primary Completion Date

December 20, 2024

Study Completion Date

October 20, 2027

Conditions
MelanomaMelanoma, UvealHead and Neck Cancer
Interventions
BIOLOGICAL

Adoptive therapy with autologous MC2 TCR T cells

Adoptive therapy with autologous MC2 TCR T cells combined with AZA/VP

Trial Locations (1)

3015GD

RECRUITING

Erasmus Medical Center, Rotterdam

Sponsors
All Listed Sponsors
collaborator

Ludwig Institute for Cancer Research

OTHER

collaborator

Dutch Cancer Society

OTHER

collaborator

Stichting Coolsingel Rotterdam grant

UNKNOWN

collaborator

Jan Ivo Stichting grant

UNKNOWN

lead

Erasmus Medical Center

OTHER